A Research Study of the Effect of Etavopivat on Other Drugs in Healthy Participants

Phase 1

Recruiting

• Conditions: Healthy Volunteers Sickle Cell Disease, Thalassemia
• Interventions: Drug: Digoxin; Drug: Midazolam; Drug: Etavopivat; Drug: Pitavastatin; Drug: Rosuvastatin; Drug: Metformin

• Registration Number: NCT06813924
• Lead Sponsor: Novo Nordisk A/S

Brief Summary

The study aims to test if a new medicine called etavopivat potentially affects other medicines in healthy participants. The purpose of the study is to investigate whether the use of etavopivat affects the breakdown and metabolism of commonly used medicines in the body. During the study, participants will receive etavopivat and five different medicines that are already approved and available on the market, and which can be prescribed by doctors. These marketed medicines are called substrate drugs and they are: digoxin, pitavastatin, metformin, midazolam, and rosuvastatin. During a period of the study, participants will take 2 tablets of etavopivat daily for 10 consecutive days. The study will last for about 34 to 64 days.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2025-02-03
• Study First Submitted QC: 2025-02-03
• Study Start: 2025-02-06
• Study First Posted: 2025-02-07
• Status Verified: 2025-06
• Primary Completion: 2025-06-10
• Study Completion: 2025-06-10
• Last Update Submitted: 2025-06-19
• Last Update Posted: 2025-06-22

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 29

Inclusion Criteria

• Body mass index (BMI) between 18.5 and 29.9 kilograms per square meter (kg/m^2) (both inclusive) at screening.
• Body weight greater than (>) 50.0 kg at screening.
• Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator.

Exclusion Criteria

• Known or suspected hypersensitivity to study interventions or related products.
• Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using adequate contraceptive method.
• Exposure to an investigational medicinal product within 30 days or 5 half-lives of the investigational medicinal product (if known), whichever is longer, before screening.
• Participant is unable to refrain from or anticipates the use of any drug known to be a moderate or strong inhibitor or inducer of uridine 5'-diphospho-glucuronosyltransferase (UGT) enzymes, CYP3A4, CYP2C9, MATE1, OATP1B1/1B3, BCRP, OCT2, or P-gp, including St. John's Wort for 28 days prior to dosing and throughout the study.
• Use of any medication with unknown or unspecified content within 90 days before screening.
• Use of or intent to use prescription medicinal products or non-prescription drugs (including vitamins and herbal supplements) within 14 days prior to dosing and throughout the study, as declared by the participant, except for:
• Adequate contraceptive methods.
• Hormone replacement therapy (HRT) (for menopausal females).
• Over-the-counter topical medications known to not reach systemic circulation.
• Occasional use of acetaminophen up to 2 grams (g) (4 x 0.5 g) daily.
• Not able or not willing to adhere to study procedures, including:
• Eating the food provided in the study.
• Refraining from ingesting food or drinks that are not allowed during the study.
• Swallowing tablets.
• Abstaining from concomitant medication not allowed during the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Period 1: digoxin+pitavastatin+metformin	Digoxin	Participants will receive a single dose of oral digoxin, pitavastatin and metformin.
Period 1: digoxin+pitavastatin+metformin	Pitavastatin	Participants will receive a single dose of oral digoxin, pitavastatin and metformin.
Period 1: digoxin+pitavastatin+metformin	Metformin	Participants will receive a single dose of oral digoxin, pitavastatin and metformin.
Period 1: midazolam+rosuvastatin	Midazolam	Participants will receive a single dose of oral midazolam and rosuvastatin.
Period 1: midazolam+rosuvastatin	Rosuvastatin	Participants will receive a single dose of oral midazolam and rosuvastatin.
Period 2: etavopivat+midazolam	Etavopivat	Participants will receive a daily dose of oral etavopivat and single dose of oral midazolam.
Period 2: etavopivat+midazolam	Midazolam	Participants will receive a daily dose of oral etavopivat and single dose of oral midazolam.
Period 2: etavopivat+midazolam+rosuvastatin	Etavopivat	Participants will receive a daily dose of oral etavopivat, single dose of oral midazolam and rosuvastatin.
Period 2: etavopivat+midazolam+rosuvastatin	Midazolam	Participants will receive a daily dose of oral etavopivat, single dose of oral midazolam and rosuvastatin.
Period 2: etavopivat+midazolam+rosuvastatin	Rosuvastatin	Participants will receive a daily dose of oral etavopivat, single dose of oral midazolam and rosuvastatin.
Period 2: etavopivat+digoxin+pitavastatin+metformin	Etavopivat	Participants will receive a daily dose of oral etavopivat, single dose of oral digoxin, pitavastatin and metformin.
Period 2: etavopivat+digoxin+pitavastatin+metformin	Digoxin	Participants will receive a daily dose of oral etavopivat, single dose of oral digoxin, pitavastatin and metformin.
Period 2: etavopivat+digoxin+pitavastatin+metformin	Pitavastatin	Participants will receive a daily dose of oral etavopivat, single dose of oral digoxin, pitavastatin and metformin.
Period 2: etavopivat+digoxin+pitavastatin+metformin	Metformin	Participants will receive a daily dose of oral etavopivat, single dose of oral digoxin, pitavastatin and metformin.

Primary Outcome Measures

Name	Time	Method
Cmax, digoxin, SD: Maximum observed digoxin plasma concentration with and without etavopivat at steady state	Day 1 and day 3 after digoxin administration	Measured as picograms per milliliter (pg/mL).
AUC0-inf, digoxin, SD: Area under the digoxin plasma concentration-time curve from 0 hours and extrapolated to infinity with and without etavopivat at steady state	Day 1 and day 3 after digoxin administration	Measured as hours\*picograms per milliliter (h\*pg/mL).
Cmax, rosuvastatin, SD: Maximum observed rosuvastatin plasma concentration with and without etavopivat at steady state	Day 1 after rosuvastatin administration	Measured as pg/mL.
AUC0-inf, rosuvastatin, SD: Area under the rosuvastatin plasma concentration-time curve from 0 hours and extrapolated to infinity with and without etavopivat at steady state	Day 1 after rosuvastatin administration	Measured as h\*pg/mL.
Cmax, midazolam, SD: Maximum observed midazolam plasma concentration without etavopivat, with a single dose of etavopivat, and with etavopivat at steady state	Day 1 after midazolam administration	Measured as pg/mL.
AUC0-inf, midazolam, SD: Area under the midazolam plasma concentration-time curve from 0 hours and extrapolated to infinity without etavopivat, with a single dose of etavopivat, and with etavopivat at steady state	Day 1 after midazolam administration	Measured as h\*pg/mL.
Cmax, pitavastatin, SD: Maximum observed pitavastatin plasma concentration with and without etavopivat at steady state	Day 1 and day 3 after pitavastatin administration	Measured as nanograms per milliliter (ng/mL).
AUC0-inf, pitavastatin, SD: Area under the pitavastatin plasma concentration-time curve from 0 hours and extrapolated to infinity with and without etavopivat at steady state	Day 1 and day 3 after pitavastatin administration	Measured as hours\*nanograms per milliliter(h\*ng/mL).
Cmax, metformin, SD: Maximum observed metformin plasma concentration with and without etavopivat at steady state	Day 1 and day 3 after metformin administration	Measured as ng/mL.
AUC0-inf, metformin, SD: Area under the metformin plasma concentration-time curve from 0 hours and extrapolated to infinity with and without etavopivat at steady state	Day 1 and day 3 after metformin administration	Measured as h\*ng/mL.

Secondary Outcome Measures

Name	Time	Method
AUC0-last, digoxin, SD: Area under the digoxin plasma concentration-time curve from 0 hours to the last quantifiable concentration with and without etavopivat at steady state	Day 1 and day 3 after digoxin administration	Measured as h\*pg/mL.
CL/Fdigoxin, SD: Apparent plasma clearance of digoxin with and without etavopivat at steady state	Day 1 and day 3 after digoxin administration	Measured as liters per hour (L/h).
tmax, rosuvastatin, SD: Time to maximum observed rosuvastatin plasma concentration with and without etavopivat at steady state	Day 1 after rosuvastatin administration	Measured as hours.
CL/Frosuvastatin, SD: Apparent plasma clearance of rosuvastatin with and without etavopivat at steady state	Day 1 after rosuvastatin administration	Measured as L/h.
Vz/Frosuvastatin, SD: Apparent volume of distribution of rosuvastatin with and without etavopivat at steady state based on plasma concentration values	Day 1 after rosuvastatin administration	Measured as L.
AUC0-last, midazolam, SD: Area under the midazolam plasma concentration-time curve from 0 hours to the last quantifiable concentration without etavopivat, with a single dose of etavopivat, and with etavopivat at steady state	Day 1 after midazolam administration	Measured as h\*pg/mL.
t1/2, midazolam, SD: Terminal half-life for midazolam without etavopivat, with a single dose of etavopivat, and with etavopivat at steady state	Day 1 after midazolam administration	Measured as hours.
tmax, midazolam, SD: Time to maximum observed midazolam plasma concentration without etavopivat, with a single dose of etavopivat, and with etavopivat at steady state	Day 1 after midazolam administration	Measured as hours.
CL/Fmidazolam, SD: Apparent plasma clearance of midazolam without etavopivat, with a single dose of etavopivat and with etavopivat at steady state	Day 1 after midazolam administration	Measured as L/h.
Vz/Fmidazolam, SD: Apparent volume of distribution of midazolam without etavopivat, with a single dose of etavopivat and with etavopivat at steady state	Day 1 after midazolam administration	Measured as L.
AUC0-inf, 1-hydroxymidazolam, SD: Area under the midazolam plasma concentration-time curve from 0 hours and extrapolated to infinity without etavopivat, with a single dose of etavopivat, and with etavopivat at steady state	Day 1 after midazolam administration	Measured as h\*pg/mL.
Cmax, 1-hydroxymidazolam, SD: Maximum observed midazolam plasma concentration without etavopivat, with a single dose of etavopivat, and with etavopivat at steady state	Day 1 after midazolam administration	Measured as pg/mL.
AUC0-last, 1-hydroxymidazolam, SD: Area under the midazolam plasma concentration-time curve from 0 hours to the last quantifiable concentration without etavopivat, with a single dose of etavopivat, and with etavopivat at steady state	Day 1 after midazolam administration	Measured as h\*pg/mL.
t1/2, 1-hydroxymidazolam: Terminal half-life for 1-hydroxymidazolam without etavopivat, with a single dose of etavopivat, and with etavopivat at steady state	Day 1 after midazolam administration	Measured as hours.
tmax, 1-hydroxymidazolam: Time to maximum observed 1-hydroxymidazolam plasma concentration without etavopivat, with a single dose of etavopivat, and with etavopivat at steady state	Day 1 after midazolam administration	Measured as hours.
Vz/F1-hydroxymidazolam: Apparent volume of distribution of 1-hydroxymidazolam based on plasma concentration values without etavopivat, with a single dose of etavopivat, and with etavopivat at steady state	Day 1 after midazolam administration	Measured as L.
AUC0-last, pitavastatin, SD: Area under the pitavastatin plasma concentration-time curve from 0 hours to the last quantifiable concentration with and without etavopivat at steady state	Day 1 and day 3 after pitavastatin administration	Measured as h\*ng/mL.
t1/2, pitavastatin, SD: Terminal half-life for pitavastatin with and without etavopivat at steady state	Day 1 and day 3 after pitavastatin administration	Measured as hours.
tmax, pitavastatin, SD: Time to maximum observed pitavastatin plasma concentration with and without etavopivat at steady state	Day 1 and day 3 after pitavastatin administration	Measured as hours.
CL/Fpitavastatin, SD: Apparent plasma clearance of pitavastatin with and without etavopivat at steady state	Day 1 and day 3 after pitavastatin administration	Measured as L/h.
Vz/Fpitavastatin, SD: Apparent volume of distribution of pitavastatin with and without etavopivat at steady state based on plasma concentration values	Day 1 and day 3 after pitavastatin administration	Measured as L.
AUC0-last, metformin, SD: Area under the metformin plasma concentration-time curve from 0 hours to the last quantifiable concentration with and without etavopivat at steady state	Day 1 and day 3 after metformin administration	Measured as h\*ng/mL.
t1/2, metformin, SD: Terminal half-life for metformin with and without etavopivat at steady state	Day 1 and day 3 after metformin administration	Measured as hours.
tmax, metformin, SD: Time to maximum observed metformin plasma concentration with and without etavopivat at steady state	Day 1 and day 3 after metformin administration	Measured as hours.
CL/Fmetformin, SD: Apparent plasma clearance of metformin with and without etavopivat at steady state	Day 1 and day 3 after metformin administration	Measured as L/h.
Vz/Fmetformin, SD: Apparent volume of distribution of metformin with and without etavopivat at steady state based on plasma concentration values	Day 1 and day 3 after metformin administration	Measured as L.
Aelast, metformin, SD%: Percentage of the metformin excreted into urine from the time of dosing to the collection time of the last measurable concentration with and without etavopivat at steady state	Day 1 and day 3 after metformin administration	Measured as percentage (%) of the metformin excreted into urine.
CLR, metformin, SD: Renal clearance of metformin	Day 1 and day 3 after metformin administration	Measured as L/h.
AUC0-tau, etavopivat: Area under the etavopivat plasma concentration-time curve during one dosing interval at single dose and at steady state	Day 1 and day 3 after etavopivat administration	Measured as h\*ng/mL.
CL/F1-hydroxymidazolam: Apparent plasma clearance of 1-hydroxymidazolam without etavopivat, with a single dose of etavopivat, and with etavopivat at steady state	Day 1 after midazolam administration	Measured as L/h.
t1/2, digoxin, SD: Terminal half-life for digoxin with and without etavopivat at steady state	Day 1 and day 3 after digoxin administration	Measured as hours.
tmax, digoxin, SD: Time to maximum observed digoxin plasma concentration with and without etavopivat at steady state	Day 1 and day 3 after digoxin administration	Measured as hours.
Vz/Fdigoxin, SD: Apparent volume of distribution of digoxin with and without etavopivat at steady state based on plasma concentration values	Day 1 and day 3 after digoxin administration	Measured as liters (L).
AUC0-last, rosuvastatin, SD: Area under the rosuvastatin plasma concentration-time curve from 0 hours to the last quantifiable concentration with and without etavopivat at steady state	Day 1 after rosuvastatin administration	Measured as h\*pg/mL.
t1/2, rosuvastatin, SD: Terminal half-life for rosuvastatin with and without etavopivat at steady state	Day 1 after rosuvastatin administration	Measured as hours.
AUC0-last etavopivat: Area under the etavopivat plasma concentration-time curve from 0 hours to the last quantifiable concentration at single dose and at steady state	Day 1 and day 3 after etavopivat administration	Measured as h\*ng/mL.
Cmax, etavopivat: Maximum observed etavopivat plasma concentration at single dose and at steady state	Day 1 and day 3 after etavopivat administration	Measured as ng/mL.
t1/2, etavopivat: Terminal half-life for etavopivat at single dose and at steady state	Day 1 and day 3 after etavopivat administration	Measured as hours.
tmax, etavopivat: Time to maximum observed etavopivat plasma concentration at single dose and at steady state	Day 1 and day 3 after etavopivat administration	Measured as hours.
V/Fetavopivat: Apparent volume of distribution of etavopivat based on plasma concentration values at single dose and at steady state	Day 1 and day 3 after etavopivat administration	Measured as L.
CL/Fetavopivat: Apparent plasma clearance of etavopivat at single dose and at steady state	Day 1 and day 3 after etavopivat administration	Measured as L/h.
C, etavopivat: Observed etavopivat plasma concentration after single and multiple doses	From day 1 to day 4 after administration of etavopivat	Measured as ng/mL.
Number of adverse events (AEs)	From first dose (day 1) until end of study (day 32)	Measured as count of events.

Trial Locations

Locations (1)

ICON-Salt Lake City; 🇺🇸 Salt Lake City, Utah, United States